intended for human consumption must not be slaughtered within 48 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use in lactating dairy cows may cause drug residues in milk. A withdrawal period has not been established for preruminating calves. Do not use in calves to be processed for veal.

PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

§ 556.227 Eprinomectin.

(a) Tolerances. The tolerances for eprinomectin B1a (marker residue) are:

1. Cattle—(i) Liver (target tissue): 1.5 parts per million.
   (ii) Muscle: 100 parts per billion.
   (iii) Milk: 12 parts per billion.

(b) Related conditions of use. See §§522.814 and 524.814 of this chapter.

(c) Related tolerances. See §556.227 of this chapter.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

21 CFR Part 524

Ophthalmic and Topical Dosage Form New Animal Drugs; Eprinomectin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Merial Ltd. The supplemental NADA provides for addition of a warning statement against the use of eprinomectin topical solution in preruminating calves intended for veal.

DATES: This rule is effective November 25, 2011.

FOR FURTHER INFORMATION CONTACT: Cindy L. Burnsteel, Center for Veterinary Medicine (HFV–130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, (240) 276–8341, email: cindy.burnsteel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096–4640 filed a supplemental NADA 144–079 for EPRINEX (eprinomectin) Pour-On for Beef and Dairy Cattle, a topical solution used for the treatment and control of internal and external parasites of cattle on pasture with persistent effectiveness. The supplemental NADA provides for addition of a warning statement against the use of eprinomectin topical solution in preruminating calves intended for veal. The NADA is approved as of September 23, 2011, and the regulations are amended in 21 CFR part 524 to reflect the approval.

Approval of this supplemental NADA did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.

The Agency has determined under 21 CFR 25.33 that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 524

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

§ 524.814 Eprinomectin.

(a) Specifications. Each milliliter (mL) contains 5 milligrams (mg) of eprinomectin.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.227 of this chapter.

(c) Special considerations. See §500.25 of this chapter.

(e) Conditions of use in cattle—(1) Amount. Apply 5 mg (1 mL) per 10 kilograms (kg) of body weight (500 micrograms/kg) applied topically along backbone from withers to tailhead.

(2) Indications for use. For treatment and control of gastrointestinal roundworms (Haemonchus placei (adult and L4), Ostertagia ostertagi (adult and L4, including inhibited L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), T. longisepicularis (adult), Cooperia oncophora (adult and L4), C. punctata (adult and L4), C. surinamensis (adult and L4), Nematodirus helvetianus (adult and L4), Bunostomum phlebotomum (adult and L4), Oesophagostomum radiatum (adult and L4), Strongyloides papillosus (adults), Trichuris spp. (adults)); lungworms (Dictyocaulus viviparous, adult and L4); cattle grubs (all parasitic stages Hypoderma lineatum, H. bovis); lice (Damaelinia bovis, Linognathus vulturni, Haematopinus euryyosphurus, Solenopotes capillatus); mange mites (Chorioptes bovis, Sarcoptes scabiei); and horn flies (Haematobia irritans). Controls and protects from reinfection of D. viviparous for 21 days after treatment and H. irritans for 7 days after treatment.

(3) Limitations. A withdrawal period has not been established for preruminating calves. Do not use in calves to be processed for veal.

Dated: November 18, 2011.

Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

BILLING CODE 4160–01–P

DEPARTMENT OF THE TREASURY
Internal Revenue Service

26 CFR Part 300
[TD 9559]

RIN 1545–BK24

User Fee To Take the Registered Tax Return Preparer Competency Examination

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Final regulations.

SUMMARY: This document contains amendments to the user fee regulations. The final regulations redesignate rules pertaining to fees for obtaining a preparer tax identification number. These final regulations also establish a